Literature DB >> 12629343

Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension.

Matthew T Gettman1, Christopher W Boelter, John C Cheville, Horst Zincke, Sandra C Bryant, Michael L Blute.   

Abstract

PURPOSE: Surgery is the most effective treatment for renal cell carcinoma with tumor thrombus but predictors of outcome and patient survival are variable. Co-morbidity may affect therapeutic decision making and survival, although to our knowledge this factor has not been studied in patients with tumor thrombus. We analyzed the Charlson co-morbidity index as a predictor of outcome after surgery.
MATERIAL AND METHODS: From 1970 to 1998, 303 patients underwent surgical resection. The Charlson index, surgical era, completeness of resection, patient age, sex, tumor level, TNM stage, grade and perinephric fat invasion were studied retrospectively as univariate and multivariate predictors of outcome.
RESULTS: The level of tumor thrombus was 0 (renal vein only) in 127 patients, and I to IV in 66, 58, 36 and 16, respectively. At 5 years overall, cause specific and metastasis-free survival were 32%, 42% and 41%, while at 10 years they were 21%, 32% and 30%, respectively. For the whole cohort significant multivariate predictors of cause specific survival were metastasis (p = 0.0001), grade (p = 0.0001), perinephric fat involvement (p = 0.02) and tumor levels 0 versus I to IV (p = 0.048). The Charlson index did not predict outcome (univariate model p = 0.65).
CONCLUSIONS: Characteristics of the primary tumor remained the most important predictors of cause specific survival in this cohort. The Charlson index did not predict cause specific survival in this cohort of surgically treated patients. Prospective assessment of co-morbidity in patients treated with surgery versus conservative therapy is warranted.

Entities:  

Mesh:

Year:  2003        PMID: 12629343     DOI: 10.1097/01.ju.0000049093.03392.cc

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

Review 1.  Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC).

Authors:  Juan I Martínez-Salamanca; Estefania Linares; Javier González; Roberto Bertini; Joaquín A Carballido; Thomas Chromecki; Gaetano Ciancio; Sia Daneshmand; Christopher P Evans; Paolo Gontero; Axel Haferkamp; Markus Hohenfellner; William C Huang; Theresa M Koppie; Viraj A Master; Rayan Matloob; James M McKiernan; Carrie M Mlynarczyk; Francesco Montorsi; Hao G Nguyen; Giacomo Novara; Sascha Pahernik; Juan Palou; Raj S Pruthi; Krishna Ramaswamy; Oscar Rodriguez Faba; Paul Russo; Shahrokh F Shariat; Martin Spahn; Carlo Terrone; Derya Tilki; Daniel Vergho; Eric M Wallen; Evanguelos Xylinas; Richard Zigeuner; John A Libertino
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

2.  Co-morbidity in general practice.

Authors:  D C Saltman; G P Sayer; S D Whicker
Journal:  Postgrad Med J       Date:  2005-07       Impact factor: 2.401

3.  Locally advanced renal cell carcinoma.

Authors:  Mohammed Al Otaibi; Simon Tanguay
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

4.  Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.

Authors:  Christopher S Hollenbeak; Lucas E Nikkel; Eric W Schaefer; Evo Alemao; Nasrollah Ghahramani; Jay D Raman
Journal:  J Manag Care Pharm       Date:  2011-10

5.  The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma.

Authors:  Ho Won Kang; Sung Min Kim; Won Tae Kim; Seok Joong Yun; Sang-Cheol Lee; Wun-Jae Kim; Eu Chang Hwang; Seok Ho Kang; Sung-Hoo Hong; Jinsoo Chung; Tae Gyun Kwon; Hyeon Hoe Kim; Cheol Kwak; Seok-Soo Byun; Yong-June Kim
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-12       Impact factor: 4.553

Review 6.  Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of death.

Authors:  David Y T Chen; Robert G Uzzo; Rosalia Viterbo
Journal:  World J Urol       Date:  2014-04-08       Impact factor: 4.226

7.  Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor.

Authors:  Kaoru Irisa; Katsuhiro Masago; Yosuke Togashi; Shiro Fujita; Yukimasa Hatachi; Akiko Fukuhara; Yuichi Sakamori; Yung Hak Kim; Tadashi Mio; Michiaki Mishima
Journal:  Med Oncol       Date:  2010-12-07       Impact factor: 3.064

8.  Simplified comorbidity score for elderly patients undergoing thoracoscopic surgery for lung cancer.

Authors:  Tomohiro Haruki; Yohei Yurugi; Makoto Wakahara; Yuki Matsuoka; Ken Miwa; Kunio Araki; Yuji Taniguchi; Hiroshige Nakamura
Journal:  Surg Today       Date:  2016-10-03       Impact factor: 2.549

9.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.

Authors:  Alexander Kutikov; Brian L Egleston; Yu-Ning Wong; Robert G Uzzo
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

10.  Impact of Charlson's comorbidity index on overall survival following tumor nephrectomy for renal cell carcinoma.

Authors:  M Hammad Ather; Syed M Nazim
Journal:  Int Urol Nephrol       Date:  2009-08-28       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.